, Volume 112, Issue 4, p 325
Date: 16 Nov 2012

Vitamin D supplementation in multiple sclerosis patients in 2012: hype or reality as an adjunctive therapy?

This is an excerpt from the content

Based on epidemiological case–control studies, vitamin D deficiency is now recognized as an independent environmental risk factor for developing multiple sclerosis (MS). Studies indicate that vitamin D, besides regulating bone homeostasis, has immunomodulatory properties thought to be beneficial in MS. It is therefore an attractive and fairly safe candidate for add-on therapy. Certain studies also point towards an inverse correlation between serum vitamin D levels and MRI disease activity or relapse rate in MS patients [1, 2].

However, is there a rationale for vitamin D supplementation in MS patients specifically, besides correcting a documented serum deficiency? One can argue that vitamin D deficiency is also present in a large proportion of the general population in the Northern hemisphere, because of insufficient sunlight exposure, and therefore, supplementation should not be restricted to MS patients only.

The article by Faridar et al. in this issue of Acta Neurologica Belgica provid